DrArnold Louie

Evaluation of the contribution of SPR719 to the killing and resistance prevention activity of azithromycin plus ethambutol-based antibiotic regimens (12-arm hollow fiber study).

Translational development of new agents alone and in combination to combat Gram-negative pathogens important in Ventilator- Associated Bacterial Pneumonia: Leveraging the Gram-negative toolbox that is

Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression

Identifying the optimal combination of macrolide-containing and macrolide-sparing oral antibiotic regimens to administer with SPR719/SPR720 to maximize the killing of macrolide susceptible and –resistant strains of Mycobacterium avium Complex (MAC)

Battelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)

Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant staphylococci.

Efficacy of the polypeptide antibiotic SPR206 when administered alone and in combination with beta-lactam partner antibiotics for the killing of multidrug-resistant nosocomial Gram-negative bacterial pathogens and the impact of combination therapy on resi

Pharmacokinetic-Pharmacodynamic Studies to Support Dose Selection for Tebipenem for the Treatment of Mycobacterium avium Complex Pulmonary Disease

Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei

Project Bioshield

A Mechanism Based Approach to Metallo beta-Lactamase Inhibition

Battelle Subcontract 778380 SAB Year 1

Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs

Ceftazidime/Avibactam plus Aminoglycoside for Ceftazidime/Avibactam Resistant KPC-3 Klebsiella pneumonia

CZ-02 pharmacodynamic studies, A New Class of Antibiotics Selectively Inhibiting Bacterial Protein Synthesis

Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding

Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome

A Preclinical Mouse Model of Acinetobacter buamannii Infection For Antibacterial Development

Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii

Can ceftazidime-avibactam be pharmacodynamically-optimized to prevent emergence of resistance by KPC3-expressing Enterobacteriaceae?

OR-DRPD-ROF2017:Combating resistant Gram-negative bacterial superbugs via omics techniques

Dose-fractionation study for AKPN001 (ATCC 43816) for plazomicin and the pharmacokinetics-pharmacodynamics of amikacin

Optimizing combination therapy for accelerate clinical cure of tuberculosis

Pharmacokinetics-Pharmacodynamics of RG-6080, a Potent Non-Beta-Lactam Beta-Lactamase Inhibitor, In Combination with Meropenem, Piperacillin, and/or Cefepime for the Killing of Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa in Neutropen

aIn vitro Hollow Fiber Pharmacodynamic Studies to Identify the Dose nd Frequency of Administration of Iclaprim that Optimizes the Killing of MRSA and Prevents the Emergence of Drug-Resistance During Therapy